Lupin has received FDA approval for generic amifampridine 10 mg tablets, bioequivalent to Firdapse, which is used to treat Lambert-Eaton myasthenic syndrome, a rare autoimmune neuromuscular disorder.
As one of the first applicants, the company is eligible for 180 days of shared generic exclusivity in the U.S. market.
Source: Lupin















